Amgen director granted 665 RSU shares

Kullman Ellen Jamison reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kullman Ellen Jamison reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. director Ellen Jamison Kullman received a grant of 665 shares of common stock as a stock-based award. The award was in the form of Restricted Stock Units (RSUs) under Amgen’s 2009 director incentive and equity incentive plans and vested immediately, with each vested RSU paid in one share of common stock rather than through an open-market purchase.

After this grant, Kullman directly holds a total of 14,535.9807 Amgen shares, which include 2,121 dividend equivalents (DEs) that are credited to her unvested RSUs and will be paid in shares as those RSUs vest, along with cash for any remaining fractional share amount.

Insider Trade Summary

Grant/Award: 665 shares

Grant/Award 1 txn

Insider Kullman Ellen Jamison

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	665	$0.00	$0.00

Holdings After Transaction: Common Stock — 14,535.9807 shares (Direct)

Footnotes (2)

1. F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
2. F2. These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

RSU grant size: 665 shares Post-transaction holdings: 14,535.9807 shares Dividend equivalents: 2,121 DEs +1 more

4 metrics

RSU grant size 665 shares Common Stock RSU award to director on May 19, 2026

Post-transaction holdings 14,535.9807 shares Total Amgen shares directly held after the grant

Dividend equivalents 2,121 DEs Credited to unvested RSUs and payable in shares upon vesting

Price per granted share $0.00 per share Compensation grant, not an open-market purchase

Key Terms

Restricted Stock Units (RSUs), dividend equivalents (DEs), Equity Incentive Plan, deferral schedule

4 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

dividend equivalents (DEs) financial

"These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."

Equity Incentive Plan financial

"under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

deferral schedule financial

"Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) director Ellen Kullman report in this Form 4?

Ellen Kullman reported receiving 665 Amgen common shares through a Restricted Stock Unit grant. The award vested immediately and was issued at no cash cost, reflecting routine director equity compensation rather than an open-market stock purchase or sale.

How many Amgen (AMGN) shares does Ellen Kullman hold after this transaction?

After the grant, Ellen Kullman holds 14,535.9807 Amgen common shares directly. This total includes shares from vested RSUs and 2,121 dividend equivalents linked to unvested RSUs that will pay out in shares as they vest.

What are the terms of the RSU grant reported by Ellen Kullman at Amgen (AMGN)?

The RSUs were granted under Amgen’s 2009 director incentive and equity incentive plans and vested immediately. Each vested RSU is paid in one share of Amgen common stock, with no purchase price, and may be deferred under a director-elected deferral schedule.

What are dividend equivalents (DEs) mentioned in Ellen Kullman’s Amgen (AMGN) filing?

Dividend equivalents are credits tied to unvested RSUs that mirror dividends on Amgen stock. Kullman’s holdings include 2,121 DEs, which will be paid out as shares of common stock upon vesting, plus a cash payment for any remaining fractional share amount.

Was Ellen Kullman buying or selling Amgen (AMGN) stock on the market in this Form 4?

The Form 4 shows a grant of 665 RSU-based shares, not an open-market trade. The shares were awarded as director compensation at a reported price of $0.00 per share, so there was no market purchase or sale involved in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 07:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kullman Ellen Jamison

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		665	A	$0	14,535.9807(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

2. These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Ellen J. Kullman	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)